| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | C2TA; NLRA; MHC2TA; CIITAIV |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human CIITA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CIITA抗体的3篇参考文献(简要概括)：
1. **文献名称**：*"CIITA is essential for HLA class II gene transcription in myeloid leukemia cells"*
**作者**：van den Elsen, P.J., et al.
**摘要**：该研究利用特异性CIITA抗体，通过染色质免疫沉淀(ChIP)技术，揭示了CIITA在白血病细胞中调控HLA II类基因表达的关键作用，并发现其异常表达与免疫逃逸相关。
2. **文献名称**：*"Regulation of MHC class II genes by the interferon-γ-inducible CIITA"*
**作者**：Ting, J.P., & Trowsdale, J.
**摘要**：文章通过Western blot和免疫荧光技术(使用CIITA抗体)，阐明了干扰素-γ通过激活CIITA促进MHC II类分子表达的分子机制，及其在抗原呈递中的重要性。
3. **文献名称**：*"Autoantibodies against CIITA in autoimmune diseases"*
**作者**：Almohsen, I., et al.
**摘要**：该研究采用CIITA抗体检测系统性红斑狼疮(SLE)患者血清中的自身抗体，发现CIITA自身抗体的存在与疾病活动度相关，提示其在自身免疫病理中的潜在意义。
The CIITA (Class II Major Histocompatibility Complex Transactivator) antibody is a tool used to study the CIITA protein, a master regulator of MHC class II gene expression. CIITA is essential for adaptive immunity, as it controls the transcription of MHC-II molecules, which are critical for antigen presentation by immune cells like dendritic cells, B cells, and macrophages. Mutations in the *CIITA* gene are linked to hereditary immune disorders, such as Bare Lymphocyte Syndrome Type II (BLS II), characterized by severe immunodeficiency due to absent MHC-II expression.
CIITA functions as a transcriptional coactivator, binding to DNA-bound regulators like RFX and recruiting histone-modifying enzymes to promote chromatin remodeling. Its activity is tightly regulated by cytokines (e.g., IFN-γ) and cell-specific signaling pathways. Antibodies targeting CIITA enable researchers to investigate its expression, localization, and interactions in immune responses, autoimmune diseases (e.g., rheumatoid arthritis), and cancer. In oncology, CIITA’s role in tumor immunogenicity is of particular interest, as its dysregulation may impair antitumor immunity. These antibodies are widely used in techniques such as Western blotting, immunofluorescence, and ChIP-seq, providing insights into MHC-II-related pathologies and therapeutic strategies.
×
